Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | FAAH | O00519 | 1/20 | 0.46 |
| ▸ | CHKA | P35790 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1732462 | 0.74 | RAB9A (0.47) | RAB9ANPC1LMNAHTTFAAH | |
| SCHEMBL13542704 | 0.71 | GAA (0.49) | RAB9ANPC1LMNAHTTMEN1 | |
| SCHEMBL2414084 | 0.70 | POLB (0.56) | RAB9ANPC1LMNAHTTFAAH | |
| SCHEMBL18376043 | 0.70 | PKM (0.64) | RAB9ANPC1CHKAMEN1KMT2A | |
| SCHEMBL4367804 | 0.69 | CHKA (0.82) | LMNACHKAMEN1KMT2AALDH1A1 | |
| SCHEMBL64588 | 0.69 | CHKA (0.82) | LMNACHKAMEN1KMT2AALDH1A1 | |
| SCHEMBL11603007 | 0.69 | MDM2 (0.52) | RAB9ANPC1LMNAHTTFAAH | |
| SCHEMBL22042582 | 0.69 | RAB9A (0.57) | RAB9ANPC1LMNAHTTCHKA | |
| SCHEMBL20189519 | 0.69 | RAB9A (0.53) | RAB9ANPC1LMNAHTTFAAH | |
| SCHEMBL17078597 | 0.69 | KDM4E (0.53) | RAB9ANPC1LMNAHTTCHKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7279576-B2 | Anti-cancer medicaments | DECIPHERA PHARMACEUTICALS, LLC (US) | 2007-10-09 | — | — | US | disclosed |
| US-7279576-B2 | Anti-cancer medicaments | DECIPHERA PHARMACEUTICALS, LLC (US) | 2007-10-09 | — | — | US | disclosed |
| US-7279576-B2 | Anti-cancer medicaments | DECIPHERA PHARMACEUTICALS, LLC (US) | 2007-10-09 | — | — | US | disclosed |
| EP-1590344-A4 | ANTI-CANCER MEDICAMENTS | DECIPHERA PHARMACEUTICALS LLC (US) | 2007-08-29 | — | — | EP | disclosed |
| EP-1590344-A2 | ANTI-CANCER MEDICAMENTS | Deciphera Pharmaceuticals, Inc. (US) | 2005-11-02 | — | — | EP | disclosed |
| US-20040176395-A1 | Anti-cancer medicaments | DECIPHERA PHARMACEUTICALS, LLC | 2004-09-09 | — | — | US | disclosed |
| WO-2004060305-A2 | ANTI-CANCER MEDICAMENTS | DECIPHERA PHARMACEUTICALS, LLC (US) | 2004-07-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040176395-A1 | Anti-cancer medicaments | ABL1, ABL2, SRC | RAB9A 2813/4885NPC1 4548/4885LMNA 4092/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.